PANBELA THERAPEUTICS INC (PBLA) Stock News

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024

PBLA stock results show that Panbela Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the second quarter...

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin American

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024

PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the first quarter ...

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

Developed in collaboration with Sanofi.

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Trial's lower-than-expected event rate suggests improved survival outcomes

Panbela Announces Poster Presentation at American Association for Cancer Research:

Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models 

Panbela Announces Transfer to OTCQB Market

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the fourth quarter...

Recap: Panbela Therapeutics Q4 Earnings

Earnings Preview: Panbela Therapeutics

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...

Panbela Therapeutics regains compliance with Nasdaq (NASDAQ:PBLA)

Panbela Therapeutics (PBLA) regains compliance with Nasdaq for bid price and publicly held shares, marking a positive development for the clinical stage...

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

Panbela Therapeutics closes ~$9M public offering of shares (NASDAQ:PBLA)

Biopharmaceutical company Panbela Therapeutics has closed ~$9M public offering of ~4.4M shares priced at $2.06 per share.

Panbela Announces Closing of Approximately $9.0 Million Public Offering

Panbela Announces Closing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

Why Is Aclarion (ACON) Stock Down 16% Today?

Aclarion stock is falling on Monday after the company issued 500,000 shares of ACON to cover principal and accrued interest from notes.

Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?

Panbela Therapeutics stock is falling on Monday after pricing a public offering for PBLA shares well below its price closing price.